Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice
David G. Motto, … , Denisa D. Wagner, David Ginsburg
David G. Motto, … , Denisa D. Wagner, David Ginsburg
Published October 3, 2005
Citation Information: J Clin Invest. 2005;115(10):2752-2761. https://doi.org/10.1172/JCI26007.
View: Text | PDF
Research Article Hematology

Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice

  • Text
  • PDF
Abstract

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening illness caused by deficiency of the vWF-cleaving protease ADAMTS13. Here we show that ADAMTS13-deficient mice are viable and exhibit normal survival, although vWF-mediated platelet-endothelial interactions are significantly prolonged. Introduction of the genetic background CASA/Rk (a mouse strain with elevated plasma vWF) resulted in the appearance of spontaneous thrombocytopenia in a subset of ADAMTS13-deficient mice and significantly decreased survival. Challenge of these mice with shigatoxin (derived from bacterial pathogens associated with the related human disease hemolytic uremic syndrome) resulted in a striking syndrome closely resembling human TTP. Surprisingly, no correlation was observed between plasma vWF level and severity of TTP, implying the existence of TTP-modifying genes distinct from vWF. These data suggest that microbe-derived toxins (or possibly other sources of endothelial injury), together with additional genetic susceptibility factors, are required to trigger TTP in the setting of ADAMTS13 deficiency.

Authors

David G. Motto, Anil K. Chauhan, Guojing Zhu, Jonathon Homeister, Colin B. Lamb, Karl C. Desch, Weirui Zhang, Han-Mou Tsai, Denisa D. Wagner, David Ginsburg

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Plasma vWF-cleaving activity and vWF multimer size distribution for ADAM...
Plasma vWF-cleaving activity and vWF multimer size distribution for ADAMTS13-deficient mice and littermate controls. (A) vWF-cleaving activity in plasma from Adamts13B/129+/+, Adamts13B/129+/–, and Adamts13B/129–/– mice measured using purified human full-length vWF as a substrate. Activity was determined by analysis of the specific vWF-cleavage product indicated by the arrow, and comparison to the pattern in the control lane with ADAMTS13 activity completed inhibited by EDTA, as indicated. Specific ADAMTS13 activity was seen in plasma from Adamts13B/129+/+ and Adamts13B/129+/– mice but not Adamts13B/129–/– mice. (B) vWF-cleaving activity in plasma from Adamts13B/129+/+, Adamts13B/129+/–, and Adamts13B/129–/– mice determined using recombinant murine GST/vWF A2 domain as a substrate, which contains the previously identified ADAMTS13 cleavage site. Activity was demonstrated by appearance of the expected cleavage product indicated by the arrow. Specific ADAMTS13 activity was seen in plasma from Adamts13B/129+/+ and Adamts13B/129+/– mice but not Adamts13B/129–/– mice. Serial dilution of Adamts13B/129+/+ plasma demonstrated sensitivity to less than 1.5% of control plasma activity. (C) The vWF multimer distribution in plasma from Adamts13B/129+/+ and Adamts13B/129–/– mice. (D) The vWF multimer distribution in plasma from Adamts13B/CN2+/+ and Adamts13B/CN2–/– mice. The approximate range of UL-vWF is indicated by the brackets.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts